Evolus Q3 revenue rises 13% on toxin and HA gel growth
EOLS•Evolus said third-quarter revenue rose 13% year over year, with global toxin revenue up about 11% and injectable HA gel revenue up nearly 40%. It reaffirmed 2026 revenue guidance of $330 million to $337 million and adjusted gross margin guidance of 67.0% to 67.5%, and set non-GAAP operating expense guidance at $210 million to $213 million.
1. Revenue growth
Evolus reported third-quarter product revenue of $77.21 million, up 13% year over year, driven by growth in toxin and injectable hyaluronic acid (HA) gels. Global toxin revenue increased about 11%, while HA gel revenue grew nearly 40% as the portfolio gained market share.
2. Profitability and outlook
The company posted its fourth consecutive quarter of positive adjusted EBITDA. It reaffirmed 2026 net revenue guidance of $330 million to $337 million and adjusted gross profit margin guidance of 67.0% to 67.5%, and updated its non-GAAP operating expense guidance to $210 million to $213 million.
3. Quarterly figures
Evolus reported a third-quarter net loss of $12.52 million, gross margin of 65.0%, adjusted gross margin of 66.1%, and gross profit of $50.69 million. The company attributed results to consumer demand, customer penetration, reorder behavior and the scalability of its digital platform.
